PACB - Pacific Biosciences of California, Inc.
2.56 0.00 (0.00%)
After hours: 4:19PM EDT
| Previous Close | 2.59 |
| Open | 2.59 |
| Bid | 2.33 x 2500 |
| Ask | 2.80 x 2500 |
| Day's Range | 2.50 - 2.61 |
| 52 Week Range | 2.02 - 5.70 |
| Volume | 362,399 |
| Avg. Volume | 991,966 |
| Market Cap | 337.592M |
| Beta | 3.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.87 |
| Earnings Date | May 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.90 |
- GlobeNewswire•3 days ago
Pacific Biosciences of California, Inc. First Quarter 2018 Financial Results Call
MENLO PARK, Calif., April 20, 2018-- Pacific Biosciences of California, Inc. will hold its quarterly conference call to discuss its First Quarter 2018 Financial Results on Wednesday, May 2, 2018, at 4:30pm ...
- Zacks•11 days ago
Pacific Biosciences Gains as HudsonAlpha Picks Sequel System
Pacific Biosciences (PACB) sees increasing use of Sequel Sequencing System in pediatric and plant biologic case studies.
- GlobeNewswire•13 days ago
HudsonAlpha Using PacBio Sequencing for Childhood Developmental Disabilities Research
MENLO PARK, Calif., April 11, 2018-- Pacific Biosciences of California, Inc., the leader in long-read, high-resolution sequencing, today announced that the HudsonAlpha Institute for Biotechnology is using ...
- GlobeNewswire•28 days ago
Pacific Biosciences Announces Ten-Unit Sequel System Order for Annoroad
MENLO PARK, Calif., March 27, 2018-- Pacific Biosciences of California, Inc., the leader in long-read, high-resolution sequencing, today announced a purchase order for 10 PacBio ® Sequel ® Systems that ...
- GlobeNewswire•last month
Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore
MENLO PARK, Calif., March 22, 2018-- Pacific Biosciences of California, Inc., the leader in long-read, high-resolution sequencing, today announced that Judge Leonard P. Stark of the U.S. District Court ...
- GlobeNewswire•last month
Study Demonstrates Potential for SMRT Sequencing to Improve the Safety of Gene Therapy Protocols
MENLO PARK, Calif., March 15, 2018-- A new publication in the journal of the American Society of Gene & Cell Therapy demonstrates the utility of Single Molecule, Real-Time Sequencing to assess the quality ...
- GlobeNewswire•last month
Pacific Biosciences Announces Issuance of U.S. Patent for Concatemer Sequencing
MENLO PARK, Calif., March 13, 2018-- Pacific Biosciences of California, Inc., the leader in long-read, high-resolution sequencing, today announced that the U.S. Patent and Trademark Office has issued U.S. ...
- Zacks•2 months ago
Pacific Biosciences Unveils New Version of Sequel Software
Pacific Biosciences (PACB) enhances performance and cost-effectiveness of the Sequel System.
- GlobeNewswire•2 months ago
Pacific Biosciences Enhances Performance and Affordability of Key Applications on the Sequel System
MENLO PARK, Calif., March 07, 2018-- Pacific Biosciences of California, Inc., the leader in long-read, high-resolution sequencing, today announced a new version of Sequel ® Software and a new polymerase. ...
- Zacks•2 months ago
Pacific Biosciences (PACB) Down 15.6% Since Earnings Report: Can It Rebound?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GuruFocus.com•2 months ago
Pacific Biosciences of California Inc (PACB) Files 10-K for the Fiscal Year Ended on December ...
Pacific Biosciences of California Inc (NASDAQ:PACB) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within ADTRAN, NN, Sparton, Allete, The Ultimate Software Group, and Pacific Biosciences of California — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ADTRAN, ...
- Zacks•2 months ago
Are Options Traders Betting on a Big Move in Pacific Biosciences (PACB) Stock?
Surging implied volatility makes Pacific Biosciences (PACB) stock lucrative to the option traders.
- GlobeNewswire•2 months ago
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
MENLO PARK, Calif., Feb. 13, 2018-- Pacific Biosciences of California, Inc. today announced that it has priced its previously announced underwritten public offering of 12,500,000 shares of its common stock ...
- Benzinga•2 months ago
9 Stocks Moving In Monday's After-Hours Session
Gainers Kadmon Holdings Inc (NYSE: KDMN ) shares are up 14 percent after announcing positive topline results from a Phase 2 study of KDO25. Vipshop Holdings Ltd – ADR (NYSE: VIPS ) shares are up 10 percent ...
- GlobeNewswire•2 months ago
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif., Feb. 12, 2018-- Pacific Biosciences of California, Inc. today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Pacific Biosciences ...
- GlobeNewswire•2 months ago
SMRT Sequencing of Human Genomes to be Showcased at AGBT Conference
MENLO PARK, Calif., Feb. 12, 2018-- Pacific Biosciences of California Inc., today announced its Single Molecule, Real-Time Sequencing technology will be demonstrated in several presentations and posters ...
- GlobeNewswire•2 months ago
Pacific Biosciences Announces Outcome of First Phase of Patent Litigation Against Oxford Nanopore
MENLO PARK, Calif., Feb. 08, 2018-- Pacific Biosciences of California, Inc. announced today that the U.S. International Trade Commission has terminated its investigation into whether Oxford Nanopore’ s ...
- ACCESSWIRE•3 months ago
Blog Exposure - MediciNova’s MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b Trial
Stock Monitor: Pacific Biosciences of California Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 05, 2018 / Active-Investors.com has just released a free research report on MediciNova, Inc. ...
- Zacks•3 months ago
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of PACB earnings conference call or presentation 1-Feb-18 9:30pm GMT
Q4 2017 Pacific Biosciences of California Inc Earnings Call
- Motley Fool•3 months ago
What's Behind Pacific Biosciences of California's Sinking Fourth-Quarter Sales
The gene-sequencing company didn't have much good news from the fourth quarter, but better days could be ahead.
- Associated Press•3 months ago
Pacific Biosciences reports 4Q loss
The Menlo Park, California-based company said it had a loss of 18 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•3 months ago
Pacific Biosciences Announces Fourth Quarter and Annual 2017 Financial Results
MENLO PARK, Calif., Feb. 01, 2018-- Pacific Biosciences of California, Inc. today announced financial results for its fourth quarter and year ended December 31, 2017.. Product, service and other revenue ...
- ACCESSWIRE•3 months ago
Pacific Biosciences of California, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 1, 2018 / Pacific Biosciences of California, Inc. (NASDAQ: PACB ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 1, 2018 ...
